EMVision adds Ramsay Health Care Australia boss to board as pivotal trial begins
Ramsay Health Care Australia CEO Carmel Monaghan has been appointed a non-executive director of the board of EMVision Medical Devices.
Stockhead
Don't miss out on the headlines from Stockhead. Followed categories will be added to My News.
Ramsay Health Care Australia CEO Carmel Monaghan joins board of EMVision Medical Devices
Monaghan has worked across hospital, corporate and global positions at Ramsay for almost three decades
Appointment comes as EMVision progresses pivotal trial for emu bedside brain scanner to diagnose stroke
Special Report: The CEO of Ramsay Health Care, Australia’s largest private hospital operator, has joined the board of EMVision Medical devices as a non-executive director.
With her appointment effective today, Carmel Monaghan, who has been CEO of Ramsay Health Care (ASX:RHC) Australia since 2020, joins the board of EMVision Medical Devices (ASX:EMV) at a pivotal time in its commercial journey.
Ramsay is Australia's largest private hospital operator and offers a range of multidisciplinary healthcare services. It also has extensive operations internationally including in the UK and Europe.
Monaghan has worked across hospital, corporate and global positions at Ramsay for almost three decades.
Before her appointment as CEO, Monaghan was group chief of staff of Ramsay’s global operations, gaining extensive experience and a comprehensive understanding of healthcare operations and strategy both in Australia and overseas.
EMVision said she also served as the group head of marketing and public affairs, driving marketing, brand and communications strategy, during which time the group grew to become a leading private healthcare operator globally.
Appointment follows start of pivotal trial
Monaghan’s appointment comes after the company kicked off a pivotal trial in March for its first commercial device – the emu bedside brain scanner, which is designed to rapidly diagnose stroke at the point-of-care.
The pivotal trial supports US Food and Drug Administration (FDA) de novo (new device) clearance for emu.
If granted clearance emu is anticipated to become the predicate device for its second device, First Responder, allowing an expedited 510(k) FDA pathway for the pre-hospital market.
EMVision this week announced it had broadened the pivotal trial for its first commercial device with activation at Mount Sinai Hospital in New York, scheduled for this month.
Mount Sinai is recognised as a leader in stroke research and treatment.
Activation of another site – Liverpool Hospital in Sydney, is in progress this week.Liverpool Hospital is recognised as one of the largest stroke referral centres in New South Wales.
All up, five world-leading hospitals are now taking part in EMVision’s pivotal trial with a sixth set to be activated shortly.
Watch: EMVision expands trial for bedside stroke scanner
A ‘transformative opportunity’
Monaghan said she looks forward to working with management and fellow directors as the company enters a pivotal phase in its commercialisation journey.
“After more than three decades in healthcare leadership, I’m especially drawn to opportunities where innovation directly addresses unmet patient needs,” she said.
“Stroke and traumatic brain injury are leading causes of global disability and disease burden and will increase with an ageing population.
“Timely access to acute care and treatment are crucial in minimising the impact of stroke and so I’m excited by the transformative opportunity that EMVision’s point-of-care neurodiagnostic products represent to improve outcomes for patients.”
EMVision chairman John Keep said Monaghan was an “exceptional addition” to EMVision’s board.
“She brings a wealth of experience across clinician engagement, corporate strategy, marketing, procurement and government relations,” he said.
“With our pivotal trial for regulatory clearance underway, the board looks forward to Carmel’s contributions as EMVision progresses through to commercialisation and growth.”
This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.
Originally published as EMVision adds Ramsay Health Care Australia boss to board as pivotal trial begins
Astral strikes more gold at Feysville
A 17-hole campaign at Kamperman in the Feysville project focused on infill drilling and tested multiple structural orientations, aiming to unlock the high-grade gold potential.
Read more
Dispelling private credit myths
As the once ‘alternative’ asset that is private credit becomes a portfolio staple, distinguishing risk from opportunity – and fact from fiction – remains a key challenge.
Read more